Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | Cost Effectiveness and Resource Allocation

Figure 4

From: Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

Figure 4

Forest Plot of studies comparing the effect of treatment with peginterferon-alfa-2a vs standard-dose peginterferon-alfa-2b for genotype 1: Peginterferon-alfa-2a showed higher SVR as compared to standard dose of peginterferon-alfa-2b as well: 42.09% versus 33.44% (RR = 1.10, IC 95% 1.01 – 1.20, assuming a fixed-effect framework).

Back to article page